Table 2.
Average acute effectiveness, assessed using the Wilcoxon signed rank test, is unchanged following each patient’s longest cluster attack remission (p = 0.2188)
| Acute outcomes in patients with remission | ||||||
|---|---|---|---|---|---|---|
| Remission patient | Attack frequency (attacks/wk) at baseline | Days of stimulation prior to first remission | Consecutive (longest) remission duration (days) | Calendar months during (longest) remission | % of attacks achieving effective therapy (# effective therapy/total treated) | |
| Before Remission | After Remission | |||||
| 1 | 45 | 212 | 322 | Feb -> Nov | 0 % (0/203) | 0 % (0/1) |
| 2 | 8 | 272 | 215 | Dec -> Aug | 62 % (18/29) | 64 % (32/50) |
| 3 | 7 | 63 | 182 | Dec -> Jun | 0 % (0/4) | 46 % (6/13) |
| 4 | 35 | 42 | 133 | Aug -> Dec | 33 % (3/9) | 7 % (2/30) |
| 5 | 16 | 238 | 280 | Jul -> Apr | 57 % (12/21) | 52 % (12/23) |
| 6 | 10 | 21 | 106 | Jul -> Nov | 38 % (11/29) | 43 % (3/7) |
| 7 | 20 | 113 | 64 | Aug -> Oct | 21 % (4/19) | 56 % (14/25) |
| 8 | 7 | 174 | 63 | Mar -> May | 47 % (14/30) | 100 % (33/33) |
| 9 | 5 | 119 | 63 | Oct -> Dec | 36 % (4/11) | 33 % (1/3) |
| 10 | 20 | 84 | 62 | Apr -> Jun | 74 % (14/19) | 91 % (29/32) |
| Avg ± SD | 17.3 ± 13.3 | 133.8 ± 86.3 | 149.0 ± 96.7 | - | 36.8 ± 31.8 % | 49.2 ± 31.8 % |
| (p = 0.2188) | ||||||